Annual Research Peptide Supply Contract: Pricing, Releases, SLAs, and Renewal Mechanics
B2B Sourcing | 2026-07-09 | 10 min read
How to structure an annual research peptide supply contract, including tier-locked pricing, scheduled releases, SLA design, change order mechanics, and renewal terms that protect both sides.
Why an annual peptide supply contract is now standard
Research peptide consumption at the lab or institutional level looks irregular from outside but is highly predictable from inside. A 12-month program will run 30-50 vials of tirzepatide, 20-30 vials of BPC-157, 15-20 vials of semaglutide, and 10-15 vials of supporting compounds. The variability is in the timing, not the total volume. Annual contracts capture that predictability in pricing and lead time.
What an annual peptide supply contract typically includes
A well-drafted annual contract covers:
- Product scope and specifications
- Forecast commitment and acceptance window
- Pricing tiers locked to the forecast
- Release schedule (monthly, quarterly, or on-call)
- Lead time SLA per release
- COA delivery SLA per release
- Deviation handling (incorporates the quality agreement)
- Change order mechanics
- Termination and renewal terms
A contract that skips any of these produces friction in the first quarter.
Section 1 — Product scope and specifications
Define the product list at the SKU level, not just compound names. The contract should pin down:
- Catalog SKU identifier
- Vial size and peptide content per vial
- Salt form and counterion
- Purity threshold
- COA scope (referencing the quality agreement)
- Packaging specification
This is also where custom synthesis SKUs are added, with their own specification.
Section 2 — Forecast commitment and acceptance window
The forecast is the buyer's most powerful lever. The contract should define:
- Initial 12-month forecast with monthly or quarterly quantities
- Forecast acceptance window (typically 30 days for stock, 60 days for custom)
- Forecast accuracy target (typically 80% minimum)
- Non-cancelable window inside the forecast period
- Rolling forecast update cadence (typically quarterly)
A 12-month forecast at 80% accuracy unlocks the deepest tier pricing. A 6-month forecast at 60% accuracy gets you a smaller discount but more flexibility.
Section 3 — Pricing tiers locked to the forecast
The contract should lock pricing at the tier triggered by the forecast. A typical structure:
| Tier | Annual volume trigger | Discount off list | | --- | --- | --- | | Pilot | <USD 10,000 | 0% (list) | | Institutional | USD 10,000-50,000 | 5-10% | | Program | USD 50,000-200,000 | 10-20% | | Strategic | USD 200,000+ | 20-30% |
The contract should also define how pricing changes if the buyer exceeds or falls short of the forecast. The standard approach is to true-up at the end of each quarter.
Section 4 — Release schedule
Define how releases are triggered:
- **Monthly auto-release** — buyer receives a fixed quantity each month without re-approval
- **Quarterly call-off** — buyer calls off a fixed quantity at the start of each quarter
- **On-call** — buyer places individual POs against the contract
The release schedule should also define the lead time trigger: for catalog SKUs, lead time starts at PO release; for custom synthesis, lead time starts at forecast acceptance.
Section 5 — Lead time SLA
Lead time SLAs are typically structured as:
- Catalog SKU: 7-14 days from PO release
- Custom synthesis: 25-45 days from forecast acceptance
- Replacement lot for COA failure: 14-21 days
- Cold-chain shipment: 48-72 hour transit duration target
A missed SLA typically triggers a service credit, not liquidated damages, for research-only products. The credit is usually 1-5% of the affected release value.
Section 6 — COA delivery SLA
The contract should define when the COA arrives:
- COA delivered with the shipment
- COA delivered within 24 hours of shipment confirmation
- COA available in a secure portal within 48 hours of shipment
A missed COA SLA is more disruptive than a missed lead time SLA, because the buyer cannot accept the lot without the COA.
Section 7 — Deviation handling
The contract incorporates the quality agreement by reference. The contract itself should add:
- Buyer's right to suspend release on deviation
- Joint investigation timeline
- Replacement lot lead time and cost
- Pricing protection on the replacement lot
This is where the contract and quality agreement meet. Make sure they are aligned.
Section 8 — Change order mechanics
The contract will need change orders over its 12-month life. Define the process:
- Change request format (typically written, signed)
- Review window (typically 5-10 business days)
- Cost allocation (each side pays its own change costs)
- Effective date of approved changes
Most institutional contracts allow 2-3 change orders per year without fee. Beyond that, a small administrative fee applies.
Section 9 — Termination and renewal
The contract should define:
- Termination for cause (payment default, repeated SLA failure, regulatory issue)
- Termination for convenience (typically 60-90 days notice)
- Cure period for terminable events
- Auto-renewal terms (typically 12-month auto-renew unless 90 days notice)
- Renewal pricing (typically re-quoted at forecast)
A clean termination clause is more important than a complex one. Most contracts end on good terms, not bad ones.
Common contract mistakes to avoid
- Locking pricing without committing to a forecast
- Defining SLAs without service credits
- Omitting the change order mechanics
- Using auto-renewal with too-short notice (30 days is too short for institutional procurement)
- Failing to incorporate the quality agreement by reference
How ZePeptide structures annual contracts
ZePeptide annual contracts include:
- Tier-locked pricing at the forecast trigger
- Quarterly release schedule with on-call flexibility
- Lead time SLA with service credits for misses
- COA delivery SLA tied to shipment
- Quality agreement incorporated by reference
- 60-day termination for convenience with 90-day renewal notice
Request a draft contract from the B2B team. Most draft cycles complete inside two weeks.
ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.